Early cranial radiotherapy may improve outcomes for patients with EGFR-mutant NSCLC and limited brain metastases
Early cranial stereotactic radiotherapy (SRT) administered with first-line osimertinib was associated with improved intracranial control and survival outcomes in patients with EGFR-mutant non-small cell lung cancer (NSCLC) and limited brain metastases, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).
A recent study presented at the IASLC 2026 World Conference on Lung Cancer suggests that early cranial stereotactic radiotherapy (SRT) combined with first-line osimertinib may improve outcomes for patients with EGFR-mutant non-small cell lung cancer (NSCLC) and limited brain metastases. The retrospective analysis of patients treated with osimertinib alone or in combination with early cranial SRT found that those who did not achieve an intracranial complete response to osimertinib had a greater overall survival benefit from the combination therapy, particularly when SRT was administered in a consolidative manner.
However, no clear overall survival benefit was observed for patients who achieved an intracranial complete response. The study also reported a notable rate of symptomatic radiation necrosis at three years (28.2%). The findings support a response-adapted approach, where patients without an intracranial complete response to osimertinib may be considered for consolidative cranial SRT.
A randomized clinical trial is currently underway to further evaluate the clinical value of consolidative SRT in this patient population.
Brief written by urgent.news from Medical Xpress's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
